mark field2 days ago2 minP2X3 cough drug: Negative Ph II = 70% loss of stock price but severe patient group may show the way.Targeting the right patient population in clinical trials is key to avoiding a false negative and giving a medicine the best chance of su...
mark fieldMay 263 minBiogen ready to write-off Nav1.7 assets in pain?The last annual report for Biogen indicates worrying signs for the future development of the latest stage Nav1.7 compound Vixotrigine.
mark fieldMay 121 minRevolutionising pain R&D by developing Precision AnalgesicsPresentation by Mark J. Field at SMI Pain Therapeutics Meeting 12th May 2020. You can find a copy of the presentation above. It covers th...
mark fieldApr 204 minCOVID19: creating a new era for 'Citizen Science'"Citizen science" is defined as "scientific work undertaken by members of the general public, often in collaboration with or under the di...
mark fieldMar 202 minP2X3 receptor antagonists pass Phase 3 trials for cough – potential also in pain?P2X3 receptor channels are attractive therapeutic targets as they are expressed in sensory neurons, activated by extracellular ATP and se...
mark fieldMar 172 minWhich companies are interested in Pain? The useful analytics below LinkedIn likes & comments.I believe LinkedIn is a great source for keeping up to date with content which can be tailored to be most relevant to you. Over the past ...
mark fieldFeb 213 minIs this still a relevant target for new pain treatments: the α2δ (Alpha2Delta) Ca2+ channel?The traditional approach to analgesic development could be described as 'exceptionally challenging', with a clinical success rate of arou...
mark fieldFeb 104 minHas a new study found a personalized approach for Nav1.7? 'Precision Analgesics' may be a better betThe difficulties of pain research are highlighted well by the tale of the Nav1.7 sodium channel, which was thought to be the ‘holy grail’...
mark fieldFeb 63 minSo Pfizer & Lilly do ask FDA to approve Tanezumab for OA pain...Just a few months ago some commentators had pronounced the death of Tanezumab and the whole anti-NGF class it leads, following years of d...
mark fieldFeb 32 minVertex discontinues development of its Nav1.8 pain drug VX-961.Deep within the Full-Year and Fourth-Quarter 2019 Financial Results for Vertex you can find this statement: “Pain: The company announced ...
mark fieldJan 282 minBig data & human biomarkers – the era of citizen scientistsThe probability of a new analgesic making it through clinical development is 2%. Five-times lower than other therapeutic areas. This woef...
mark fieldJan 282 minApproval of new pain drug shows the path for analgesic innovationThe new Novartis medicine Adakveo® (crizanlizumab)has just been approved by the FDA to reduce frequency of pain crises in individuals liv...
mark fieldJan 283 minPatient-Inspired R&D – the missing part of patient engagementPatient engagement is the ‘hot topic’ within the pharma industry over the last few years, with every company, Biotech, CRO and consultant...
